Alzamend Neuro (ALZN) Expected to Announce Quarterly Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) will likely be announcing its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last released its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Price Performance

Shares of ALZN stock opened at $1.01 on Friday. The company’s 50-day moving average price is $1.00 and its 200-day moving average price is $1.33. Alzamend Neuro has a twelve month low of $0.64 and a twelve month high of $15.06.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets decreased their target price on shares of Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, March 17th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.